The Epoch Times
By
September 1, 2021 Updated: September 1, 2021
The first patient got dosed in a clinical trial analyzing Pfizer’s oral COVID-19 drug, the company announced Wednesday.
The phase 2/3 study is analyzing a protease inhibitor currently known as PF-07321332. The drug is meant to combat COVID-19 in patients who experience symptoms from the disease but do not require hospital care.
The randomized, double-blind trial will enroll about 1,140 participants, approximately half of whom will receive a placebo. The participants will get the drug or the placebo every 12 hours orally for five days.